Clinical Trials
63 trialsNCT03899155 2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT03768063 2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03694262 2026-04-13
EndoBARR
Medical College of Wisconsin
Phase 2 Completed
NCT02873962 2026-04-01
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03617679 2026-03-24
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
University of Colorado, Denver
Phase 2 Completed
NCT04539327 2026-03-18
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Grupo Español de Investigación en Cáncer de Ovario
Completed
NCT03559049 2026-02-12
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT03542175 2025-12-08
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04276376 2025-12-01
ARIANES
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT04624178 2025-11-20
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02975934 2025-07-25
TRITON3
pharmaand GmbH
Phase 3 Completed
NCT03522246 2025-06-24
ATHENA
pharmaand GmbH
Phase 3 Active not recruiting
NCT03442556 2025-06-12
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
University of Washington
Phase 2 Terminated
NCT02678182 2025-06-10
PLATFORM
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting
NCT03639935 2025-06-03
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03845296 2025-05-21
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Completed
NCT04253262 2025-05-04
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Brown University
Phase 1/2 Active not recruiting
NCT04209595 2025-03-17
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03552471 2025-02-13
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04826198 2024-12-05
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Terminated
NCT04227522 2024-11-15
MAMOC
North Eastern German Society of Gynaecological Oncology
Phase 3 Completed
NCT03958045 2024-10-22
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
University of Kentucky
Phase 2 Completed
NCT03413995 2024-10-16
TRIUMPH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03911453 2024-10-03
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
University of Arizona
Phase EARLY_PHASE1 Completed
NCT01074970 2024-09-19
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Hoosier Cancer Research Network
Phase 2 Completed
NCT03337087 2024-05-17
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
Phase 1/2 Active not recruiting
NCT04676334 2024-05-07
CATCH-R
pharmaand GmbH
Phase 3 Completed
NCT03533946 2024-03-13
ROAR
University of Utah
Phase 2 Terminated
NCT03476798 2024-02-15
Clovis-001
University of Oklahoma
Phase 2 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT03992131 2024-01-16
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
pharmaand GmbH
Phase 1/2 Terminated
NCT03840200 2023-10-30
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Hoffmann-La Roche
Phase 1 Completed
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT03140670 2023-09-28
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT04179396 2023-06-29
RAMP
pharmaand GmbH
Phase 1 Completed
NCT02042378 2023-06-13
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
pharmaand GmbH
Phase 2 Completed
NCT01891344 2023-06-12
ARIEL2
pharmaand GmbH
Phase 2 Completed
NCT03824704 2023-06-12
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
Phase 2 Terminated
NCT01482715 2023-06-09
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
pharmaand GmbH
Phase 1/2 Completed
NCT01968213 2023-06-09
ARIEL3
pharmaand GmbH
Phase 3 Completed
NCT02740712 2023-06-09
DDI
pharmaand GmbH
Phase 1 Completed
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT02935634 2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2 Completed
NCT02952534 2023-06-09
TRITON2
pharmaand GmbH
Phase 2 Completed
NCT02986100 2023-06-09
AME
pharmaand GmbH
Phase 1 Completed
NCT03397394 2023-06-09
ATLAS
pharmaand GmbH
Phase 2 Terminated
NCT03499444 2023-06-09
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
pharmaand GmbH
Phase 1 Completed
NCT03521037 2023-06-09
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
pharmaand GmbH
Phase 1 Completed